Navigation Links
Oramed Pharmaceuticals to Present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference; Tel Aviv, Israel, 2012
Date:5/21/2012

JERUSALEM, Israel, May 21, 2012 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB), a developer of oral delivery systems, announced today that it was chosen to present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference taking place in Israel on May 21-23, 2012. The presentation will be given by Nadav Kidron, Oramed's President and CEO, on Wednesday, May 23rd, at 12:10 p.m. (IDT) during the BioPharma Session.

Event: 11th National Life Science & Technology Week ILSI-BIOMED Conference

Location: David InterContinental Hotel, Tel-Aviv, Israel. 

Date: Wednesday, May 23, 2012

Time: 12:10 p.m. (IDT), or 5:10 a.m. (EST) 

For more information on the upcoming ILSI Biomed conference, please visit their website:  http://www2.kenes.com/biomed/pages/home.aspx

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 clinical trials, and with its GLP-1 analog capsule, currently entering Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem.  

For more information, the content of which is not part of this press release, please visit  http://www.oramed.com

Safe Harbor forForward-looking statements: Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Included therein are the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward-looking statements. The company undertakes no obligation to update or revise any forward-looking statements. 

Company and Investor Relations Contact:
Oramed Pharmaceuticals
Aviva Sherman
USA:   +1-646-240-4193
Int'l: +972-2-566-0001
       +972-54-792-4438
E-mail: aviva@oramed.com



'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oramed Pharmaceuticals Granted Australian Patent for Important Part of the Companys Core Technology in Oral Delivery of Proteins
2. Oramed Pharmaceuticals Files US Patent Application for Combination Oral Treatment of Diabetes
3. Oramed Pharmaceuticals Announces Successful Phase 1 Clinical Trial Results for EnteraBio
4. Oramed Pharmaceuticals Chosen to Present at the 8th Annual Israel Strategic Partner and Venture Conference on September 22, 2011
5. Oramed Pharmaceuticals to Present at Rodman & Renshaw 13th Annual Global Investment Conference
6. Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule
7. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
8. Oramed Pharmaceuticals to Present at the 70th Scientific Sessions of the American Diabetes Association
9. Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd.
10. Oramed Pharmaceuticals Expands Scientific Advisory Board With the Appointment of John Amatruda, M.D.
11. Oramed Pharmaceuticals Announces Filing of Two Registration Statements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... F ast access to ... at the point of need   ... products and services, has launched a ClinicalKey mobile app that ... device. Elsevier designed the mobile app to allow users to select access ... Android and iOS formats for mobile phone and ...
(Date:2/11/2016)... , Feb. 11, 2016  Delcath Systems, ... and medical device company focused on oncology with ... metastatic liver cancers, announces the engagement of ... Company,s Global Medical Consultant. Dr. Birgerson will provide ... Company,s clinical operations team to help ensure timely ...
(Date:2/11/2016)... , Feb. 11, 2016 SI-BONE, ... use of the iFuse Implant System, a minimally ... certain disorders of the sacroiliac (SI) joint, announced ... cost benefits of MIS SI joint fusion for ... to degenerative sacroiliitis or SI joint disruption.  In ...
Breaking Medicine Technology:
(Date:2/12/2016)... AZ (PRWEB) , ... February 12, 2016 , ... Dignity ... Arizona General Hospital Emergency Room –Mesa. The new facility is licensed under ... , “Dr. Bingham is an excellent leader and will ensure our new freestanding ...
(Date:2/11/2016)... ... 2016 , ... According to an article published February 1st on ... supplement, is being recalled due to the discovery that it contains dangerous adulterants. According ... single supplement on the market proven to help people safety lose excess weight, such ...
(Date:2/11/2016)... ... February 11, 2016 , ... Registered nurses, licensed practical nurses and ... “Stroke Management: Time to Act, Time to Heal” on Thursday, February 25 from 9:00 ... The presenter is Vishal Chedda, president of ANSA Consultants, who will discuss clinical best ...
(Date:2/11/2016)... ... ... Journal of Pain Research has seen a significant increase in its ranking ... Scopus database (Elsevier B.V.) and is a measure of a journal's impact. It takes ... year period and also the importance of the journals where the citations came from. ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... the healthcare industry, ranked among the top five firms in the “2015/2016 Best ... HIT Implementation Support and Staffing. KLAS is a research and insights firm on ...
Breaking Medicine News(10 mins):